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Abstract
Fatigue is one of the most common and debilitating complaints of HIV-positive individuals, potentially leading to
important functional limitations. We recruited 128 HIV-positive individuals (fatigued and nonfatigued) between
March 2005 and May 2006; 66% were male, 66% were African American, 45% had greater than a high school
education, 67% were unemployed, and ages ranged from 26–66 (median, 44). Every 3 months for 15 months,
participants completed a 56-item self-report fatigue scale developed and validated by the authors. Participants
were classified as fatigued or not fatigued at each assessment and received scores for fatigue intensity and impact
of fatigue on functioning. We used linear mixed-effects models to assess longitudinal variation in fatigue scores
and generalized estimating equations for binary outcomes to model predictors of fatigue remission among those
fatigued at baseline. At baseline, 88% of the sample was fatigued. Fatigue measures were highly correlated across
time points (r 0.63–0.85 [intensity], 0.63–0.80 [functioning]) and showed no evidence of overall improvement,
deterioration, or convergence over time. Predictors of lower fatigue scores included higher income, employment,
longer time since HIV diagnosis, and antiretroviral therapy use. Those employed at baseline were likely to show
improvements in fatigue while those unemployed were not. Of those fatigued at baseline, 11% experienced
remission during follow-up; remission was associated with Caucasian race and employment. In summary, fatigue
intensity and related functional limitations were persistent, stable, and unlikely to remit over 15 months of follow-
up in this sample of patients with established HIV infection.
Introduction
In the present era of long-term medical management ofHIV infection, fatigue has emerged as one of the most
common and debilitating complaints of people infected with
HIV. Estimates of the prevalence of fatigue in HIV-positive
individuals when measured by self-report generally range
from 55% to 65%, with similar estimates reported both before
and since the advent of highly active antiretroviral therapy.1–5
While some develop fatigue early in HIV infection, others
develop fatigue with disease progression.6 The consequences
of fatigue include having to stop working, limiting one’s in-
volvement with family and friends, being unable to manage
one’s finances, and needing an entire day to get through the
simplest of household chores.7–9 Justice et al.10 found that
fatigue was the most common symptom among people with
HIV infection, reported by 67% of respondents, and that fa-
tigue was associated with functional limitation and higher
mortality.
Despite the clinical and functional relevance of fatigue,
little research has been published regarding the persistence
and remission of fatigue in HIV-positive individuals. The
natural variation in fatigue symptoms over time and the
propensity of fatigue to remit in the absence of direct inter-
vention are questions of some importance for the clinical
management of patients with HIV infection.
Accordingly, in the present study, we completed detailed
assessments of the intensity of fatigue and the impact of fa-
tigue on daily functioning over 15 months of follow-up in a
sample of patients with established HIV infection to assess
the natural course of fatigue and the predictors of fatigue
remission.
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We report results from a prospective observational co-
hort study of the causes and consequences of fatigue in
HIV-positive individuals that has been described in detail
previously.11 Participants were recruited via flyers advertis-
ing the study at HIV=AIDS treatment centers and service or-
ganizations in a small metropolitan area of a southern state.
While fatigue was prominent on the flyer, we stated that we
were searching for both fatigued and nonfatigued people.
Interested individuals were invited to participate if they met
the following inclusion criteria: (1) HIV-positive, (2) 21 years
or older, (3) able to read and speak English competently, and
(4) judged mentally competent to provide reliable data by the
principal investigator ( J.B.). Both fatigued and nonfatigued
individuals were eligible to enroll. Individuals were excluded
if they had a comorbid condition marked by fatigue such as
renal disease, cancer, or multiple sclerosis. Pregnant women
and women less than 12 months postpartum were also ex-
cluded. Of the 150 interested individuals who expressed in-
terest and met eligibility criteria, 128 (85%) enrolled in the
study and completed the baseline assessment between March
2005 and May 2006.
Participants attended study visits in the General Clinical
Research Center of an academic medical center at baseline and
at 6-month intervals thereafter. At these visits, participants
completed assessments of fatigue, sleep quality, depression,
anxiety, symptoms of posttraumatic stress disorder, stress,
social support, common medical symptoms, and general
health. Participants also provided a blood sample for the
quantification of a range of biomarkers of hepatic, thyroid,
immunologic, gonadal, and hematologic function as well as
HIV viral load, serum cortisol, and cellular injury; all labo-
ratory results were provided to the treating clinician for any
necessary clinical follow-up. At baseline, additional infor-
mation about demographics and lifetime trauma exposure
were collected. Supplemental fatigue assessments were com-
pleted at home at the midpoint between study visits and
mailed in. Participants received $70 in compensation for each
study visit and $20 for completing each fatigue questionnaire
by mail. Data available for this analysis extended through 15
months of follow-up, comprising 3 in-person fatigue assess-
ments (0, 6, and 12 months) and 3 assessments by mail (3, 9,
and 15 months). All study procedures were approved by the
Duke University Institutional Review Board, and all study
participants provided written informed consent.
Measures
Fatigue. The HIV-Related Fatigue Scale (HRFS),12 a
Likert-type 56-item self-report measure with a seventh-grade
reading level, was used to measure fatigue intensity, the
impact of fatigue on functioning, and the circumstances sur-
rounding fatigue. In psychometric assessments, the HRFS
demonstrated high internal consistency and satisfactory con-
vergent validity when compared with other measures of fa-
tigue and related constructs.13 The 8-item fatigue intensity
scale of the HRFS (Cronbach a 0.93) includes Likert scale-rated
items such as the respondent’s level of fatigue today and most
days, the severity of the fatigue, and the extent to which fatigue
has caused problems or distress. The 22-item scale measuring
the impact of fatigue on daily functioning (Cronbach a 0.97)
asks about the extent to which fatigue has impaired activities of
daily living (ADLs; e.g., cooking, bathing, dressing, exercis-
ing), socialization (e.g., visiting=socializing, interactions with
others outside home, sexual activity), and mental functioning
(e.g., thinking clearly, concentration). Both the intensity of fa-
tigue and its impact on functioning are of clinical relevance:
some subjects may be very fatigued, but are able to minimize
its impact on their cognitive and social functioning and the
completion of activities of daily living. Higher scores indicate
more intense fatigue or greater impact of fatigue; each scale
ranges from 1 to 10. Although we conceptualize fatigue in-
tensity and impairment of functioning as continuous rather
than categorical constructs, for descriptive purposes we also
examined the proportion of individuals scoring 7 or more on
each scale as a proxy for severe fatigue and impairment.
Subjects whose intensity of fatigue was low (1 or 2 out of 10)
on all of the first 7 HRFS items (e.g., my level of fatigue today;
my level of fatigue on most days; how severe is the fatigue)
were coded as not fatigued at that time point and were as-
signed a value of 1 on all remaining items. Among those
presenting as fatigued at baseline, we classified any individ-
ual presenting as not fatigued at a later time point as experi-
encing remission at that time.
Other variables. Patients reported sociodemographic and
certain clinical information (e.g., age, race, education, when
diagnosed with HIV infection, and current antiretroviral
therapy [ART] status) in interviews with one of two research
assistants. Plasma samples were analyzed using standard
methods to measure CD4þ cell count and HIV RNA viral
load (VL).
Analyses
We used analytic methods appropriate for repeated ob-
servations with normally distributed and dichotomous de-
pendent variables. We used linear mixed-effects models to
assess (1) the overall trend in fatigue scores over time, (2)
individual and group variation in fatigue score trajectories,
and (3) predictors of fatigue scores. We used likelihood ratio
tests with appropriate mixed w2 distributions14 that compared
nested models to assess whether inclusion of random inter-
cepts (indicating individual variation in overall fatigue levels)
and random slopes (indicating individual variation in fatigue
trajectories over time) contributed to the fit of the models. We
used interaction terms with time to assess whether there were
differences in fatigue trajectories between groups.
Among those patients presenting with fatigue at base-
line, we used generalized estimating equation (GEE) models
with a logit link, binomial error distribution, and exchange-
able working correlation structure to examine predictors of
fatigue remission at subsequent visits. Because remission was
a relatively rare event, we used a two-stage model building
process to avoid overfitting. First, two groups of covariates
were considered in separate models: sociodemographic (age,
gender, race, years of education, log-transformed income, and
employment status) and clinical (years since HIV diagnosis,
ART status, and CD4 count). Viral load was not included in
multivariable models due to high correlation with ART status.
Covariates with a p value <0.20 in each model were then
combined. All models further included baseline fatigue in-
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tensity score, time since baseline, and assessment method (in-
person versus mail-in fatigue assessment).
Results
Description of sample
The demographic characteristics of the sample reflect the
HIV epidemic in the southeastern United States. Participants
were primarily between 30 and 50 years of age. Approxi-
mately two thirds of participants were male and approxima-
tely two thirds were African American, with the remainder
predominantly Caucasian (Table 1). Over half the sample had
a high school education or less, and only one third was em-
ployed at baseline. Primary HIV risk factors included being a
man who had sex with men (39%) and heterosexual contact
(32%), with injection drug use playing a relatively minor role
in this population (9%). The sample primarily comprised
people who had lived with HIV infection for a long time, with
a median of 10 years since diagnosis (range, 0–25 years). A
large majority was on antiretroviral therapy at baseline and
had high CD4 counts and HIV RNA viral loads less than 400
copies per milliliter. Eighty-eight percent of the sample was
fatigued at baseline.
Fatigue over time
Retention between 3 and 15 months ranged between 78%
and 88% (Table 2). Of the 15 participants (12%) who did not
complete the most recent in-person interview (at 12 months), 1
had died, 2 had moved away from the area, 3 had requested to
withdraw from the study, and 9 could not be located. Baseline
values for fatigued versus nonfatigued status, fatigue inten-
sity, and fatigue-related impairment of functioning did not
predict retention at any time point. Men were more likely to
complete follow-up than women at 3 and 6 months but this
difference was no longer evident at later time points. Those
reporting a current alcohol problem were less likely to be
retained at some time points (3, 6, 15 months) but not others
(9 and 12 months).
Overall, the average level of fatigue intensity in the sample
remained relatively stable over 15 months of follow-up,
ranging between 5.6 and 6.1 on a 1–10 scale (Table 2). Between
30% and 43% of individuals reported fatigue intensity 7 or
greater at each time point. The average level of impact of
fatigue on functioning ranged between 4.8 and 5.3 over
the same period, with 23%–27% of participants scoring 7 or
greater at each time point. For both scales, slightly higher
fatigue scores were reported on the mail-in surveys (months
3, 9, and 15) than at in-person visits (months 0, 6, and 12),
and the average fatigue level fell slightly from baseline to the
6-month visit but remained stable between the 6- and 12-
month visits.
If fatigue were highly variable over time, we would expect to
see convergence over time between those who had the highest
and lowest fatigue scores at baseline. Instead, participants’








Male gender 84 (65.6%)
Race:












Heterosexual sex 42 (32.8%)
IDU 12 (9.4%)
Other=multiple=don’t know 24 (18.8%)
Clinical













Fatigued at baseline 111 (88.1%)
Experienced remission of fatigue
during follow-upa
11 (10.7%)
aOf 103 participants fatigued at baseline and with at least one
follow-up visit.
IQR, interquartile range.
Table 2. Changes in Fatigue Intensity and Impact of Fatigue on Functioning Over 15 Months of Follow-Up
Fatigue intensitya Impact of fatigue on functioninga
Assessment n Mean (SD) % scoring  7 Mean (SD) % scoring  7
Baseline 126 5.85 (2.17) 30.2 5.10 (2.44) 24.6
3-month mail-in 113 6.14 (2.36) 43.4 5.29 (2.33) 27.0
6-month visit 109 5.57 (2.37) 34.9 4.78 (2.57) 21.1
9-month mail-in 100 6.00 (2.43) 39.0 5.16 (2.39) 26.0
12-month visit 111 5.61 (2.33) 33.9 4.86 (2.47) 23.2
15-month mail-in 107 5.95 (2.34) 41.1 5.33 (2.37) 27.1
aMeasured on a 1–10 scale.
SD, standard deviation.
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initial fatigue scores were highly predictive of the course of
their fatigue over the subsequent 15 months. Figure 1A and 1B
show scores for fatigue intensity and impact of fatigue on
functioning over time, separated by quintile of baseline fa-
tigue. While some regression to the mean was evident over the
first three months, the differences between the quintiles re-
mained remarkably stable between months 3 and 15. The in-
dividuals with fatigue scores in the lowest quintile at baseline
(mean intensity 2.34) had a mean intensity score of 3.34 at 3
months and the same mean at 15 months. The individuals with
fatigue scores in the highest quintile at baseline (mean inten-
sity 8.44) improved slightly to a mean intensity score of 8.11 at
3 months and 7.81 at 15 months. Indeed, correlations between
fatigue measures at the 6 time points were universally high,
ranging between 0.63–0.85 for fatigue intensity and between
0.63–0.80 for impact of fatigue on functioning (Table 3).
In multivariable linear mixed-effects models, there was no
evidence of change over time in the sample’s mean fatigue
scores (intensity: b¼0.01 [95% confidence interval {CI}
0.03, 0.01] per 6 months; impact of fatigue on functioning:
b¼ 0.00 [0.02, 0.02]; Table 4). Predictors of overall lower
fatigue scores included higher income, employment, longer
time since HIV diagnosis, and receipt of antiretroviral ther-
apy. As expected, there was evidence of individual variation
in overall fatigue levels on both scales, as indicated by likeli-
hood ratio tests evaluating the contribution of random inter-
cepts to the mixed-effects model ( p values <0.001 for both
scales). There was no evidence of individual variation in tra-
jectories of impact of fatigue on functioning over time, as in-
dicated by a likelihood ratio test evaluating the contribution
of random slopes to the model ( p¼ 0.91). However, there
was evidence of individual variation in trajectories of fatigue
intensity over time ( p¼ 0.03). Most of the individual pre-
dicted changes were relatively small in magnitude, ranging
from a minimum of a 1.7-point predicted decrease to a max-
imum of a 0.8-point predicted increase in fatigue intensity
over 15 months (interquartile range: 0.5 to 0.2).
We found little evidence of variation in fatigue trajectories
between groups defined by sociodemographic or clinical
characteristics. Only for employment status was an interac-
tion term with time statistically significant. Individuals em-
ployed at baseline tended to achieve small improvements in
fatigue intensity (0.29 [0.48, 0.10]) and impact on func-
tioning (0.21 [0.42, 0.00]) over time whereas those unem-
ployed did not (0.03 [0.10, 0.17] and 0.08 [0.07, 0.23]; data
not shown). For all other groups, average scores for fatigue
Table 3. Correlations Between Repeated Fatigue Measures Over 15 Months
Baseline 3 months 6 months 9 months 12 months 15 months
Fatigue intensity
Baseline 1.00
3 months 0.72 1.00
6 months 0.67 0.73 1.00
9 months 0.63 0.73 0.75 1.00
12 months 0.70 0.76 0.78 0.79 1.00
15 months 0.70 0.73 0.78 0.80 0.85 1.00
Impact of fatigue on functioning
Baseline 1.00
3 months 0.67 1.00
6 months 0.71 0.65 1.00
9 months 0.65 0.63 0.71 1.00
12 months 0.72 0.65 0.74 0.72 1.00
15 months 0.72 0.70 0.78 0.69 0.80 1.00
FIG. 1. Fatigue intensity (A) and impact of fatigue on
functioning (B) over 15 months of follow-up, by quintile of
baseline fatigue.
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intensity and impact of fatigue on functioning remained sta-
ble over time.
Predictors of remission
Remission of fatigue was a relatively rare event. Of 103
participants who were fatigued at baseline and completed at
least one follow-up visit, only 11 were ever classified as not
fatigued during 15 months of follow-up. In multivariable GEE
models controlling for time and baseline fatigue intensity,
individuals of African American race were less likely to ex-
perience remission of their fatigue while those employed at
baseline were more likely to experience remission (Table 5).
Given the small number of remission events, the associated
confidence intervals were quite wide.
Discussion
While fatigue is increasingly being recognized as one of the
most common and debilitating symptoms accompanying
chronic HIV infection, little longitudinal data exists on the
course and persistence of fatigue over time in HIV-infected
individuals. In this prospective cohort of patients with long-
term HIV infection, we observed a high level of persistence
of fatigue, with only 11% of fatigued participants experi-
encing remission of their fatigue over 15 months of follow-up
and with fatigue intensity showing little variation over the
same time period. We observed high correlations in fatigue
scores measured at 3-month intervals over 15 months: the in-
dividuals with the highest fatigue scores at baseline consis-
tently remained the most fatigued over time. We are unaware
of any previous research which has described the natural
course of HIV-related fatigue over such an extended time
period.
The persistence of fatigue has important implications for
clinical management. HIV-related fatigue in this sample was
unlikely to remit spontaneously in the absence of direct in-
tervention, lending added urgency to efforts to understand
the etiology of HIV-related fatigue and to identify interven-
tion points. In baseline analyses from the present study, we
identified no associations between fatigue and a wide range
of physiological factors.11 In contrast, depression, stress, and
traumatic experiences were strongly associated with variation
in fatigue levels.15
Consistent with baseline analyses from this sample, we
found that higher income and being employed at base-
line were predictive of lower average fatigue levels over the
follow-up period. However, the direction of causality cannot
be unequivocally determined even from these prospective
data given the clear persistence of fatigue over time. This as-
sociation may indicate that Individuals with more chronic
fatigue are less likely to be employed (and therefore have
lower incomes), that higher-paying jobs are less physically
demanding, or that those with more disposable income
are able to hire help to relieve themselves of fatiguing obli-
gations.
Table 4. Multivariable Linear Mixed Models of Fatigue Intensity and Impact on Functioning Over 15 Months
Intensity Impact on functioning
Predictor Coefficient 95% CI Coefficient 95% CI
Time since baseline, per 6 months 0.01 (0.03, 0.01) 0.00 (0.02, 0.02)
Mail-in (vs. in-person) assessment 0.39 (0.20, 0.57) 0.36 (0.14, 0.57)
Age, per 10 years 0.19 (0.26, 0.64) 0.25 (0.21, 0.70)
Male gender 0.05 (0.72, 0.61) 0.28 (0.39, 0.95)
African American race 0.05 (0.73, 0.64) 0.04 (0.65, 0.73)
Education, per year 0.04 (0.18, 0.10) 0.02 (0.16, 0.12)
Income, per log10 0.43 (0.77, 0.09) 0.60 (0.94, 0.25)
Employed 1.16 (1.90, 0.41) 1.33 (2.08, 0.58)
Years since HIV diagnosis, per year 0.06 (0.12, 0.01) 0.08 (0.13, 0.02)
On antiretroviral therapy 1.10 (1.89, 0.32) 0.85 (1.65, 0.06)
CD4, per 100 cells=mm3 0.06 (0.15, 0.03) 0.04 (0.12, 0.05)
Intercept 8.96 (6.32, 11.61) 7.62 (4.94, 10.29)
Random-effects parameters
Intercepts: SD (95% CI) 1.55 (1.31, 1.83) 1.57 (1.36, 1.81)
Coefficients: time since baseline: SD (95% CI) 0.06 (0.04, 0.10)
Correlation (95% CI) of intercepts and coefficients 0.03 (0.43, 0.38)
Likelihood ratio test statistics ( p value)
Inclusion of random intercepts 384.39 (< 0.001) 309.82 (< 0.001)
Inclusion of random coefficients (time since baseline) 7.32 (0.016) 0.19 (0.786)
CI, confidence interval; SD, standard deviation.
Table 5. Predictors of Remission of Fatigue
Remission










African American race 0.23 (0.06, 0.80)




OR, odds ratio; CI, confidence interval.
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Individuals with more established HIV infection had less
fatigue on average, which could reflect the natural history of
HIV infection, a survival bias, or the development of coping
strategies over time. Receipt of antiretroviral therapy was also
associated with less fatigue, although it cannot be determined
from these data whether successful management of HIV re-
duces fatigue or whether individuals with less (or less
chronic) fatigue are more likely to receive ART, perhaps be-
cause of a greater ability to engage reliably in medical care.
African Americans were only one fourth as likely as those
of other races (primarily Caucasians) to experience remission
of fatigue during the study period. Although there were no
racial differences in scores of fatigue intensity or impact of
fatigue on functioning in multivariable analyses, we did ob-
serve racial disparities for both scores in bivariable analyses;
these differences were eliminated after adjustment for edu-
cation, income, and employment status. It is possible that the
relationship between race and remission is similarly mediated
by socioeconomic factors but that the small number of re-
mission events in this analysis made our models of remission
unstable. We are unaware of other studies that have described
racial disparities in HIV-related fatigue.
It should be noted that the self-referral method of recruit-
ment in this study may have resulted in a sample biased to-
ward individuals with fatigue as well as those with more
chronic fatigue. Thus the results of this study may be an
overestimate of the prevalence and chronicity of fatigue among
HIV-positive individuals generally. Further research on the
natural course of fatigue in other samples is warranted.
Nevertheless, this analysis indicates that there is at least a
subset of HIV patients for whom chronic fatigue is a sub-
stantial and enduring concern.
Fatigue remains a challenging construct to measure defin-
itively, with no generally accepted gold standard definition.
The HRFS used in this study is a detailed instrument devel-
oped through careful formative qualitative research and de-
signed specifically to measure the intensity and consequences
of fatigue in HIV-positive individuals.12 The HRFS has dem-
onstrated strong internal consistency and good convergent
and construct validity.13
In summary, the present study highlights a high level of
stability and persistence of fatigue symptoms over 15 months
in a sample of HIV-positive patients. A number of studies
have demonstrated the high prevalence and debilitating
consequences of fatigue for HIV-positive individuals, and the
present study makes clear that at least in a subset of patients,
fatigue symptoms are unlikely to resolve on their own. Fur-
ther attention to understanding the etiology of HIV-related
fatigue and identifying intervention points is warranted.
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